Tenbager for the next 10 years, preferred innovative drugs, vaccines, medical devices and medical services industry.
1, anti-tumor innovative drugs (biopharmaceuticals).
Hengrui Medicine (SH:600276), Beida Pharmaceuticals (SZ:300558), China Biopharmaceuticals (HK:01177), Henson Pharmaceuticals (HK:03692), and Cinda Bio (HK:01801).
2. CRO (CXO) contract research organization that provides professional services for the entire process of clinical trials for new drug development.
Weiming Kande (SH:603259), Tiger Pharma (SZ:300347), Kanglong Huacheng (SZ:300759), Kaleidin (SZ:002821), and Medicine Stone Technology (SZ:300725).
3, biological vaccines.
Changchun Hi-Tech (SZ:000661), Zhifei Biological (SZ:300122), Kangtai Biological (SZ:300601), Watson Biological (SZ:300142), Hualan Biological (SZ:002007).
4, eye medical services.
Aier Ophthalmology (SZ:300015), OPPKV (SZ:300595).
5, oral medical services.
Tongze Medical (SH:600763), Meiya Optoelectronics (SZ:002690), Zhenghai Bio (SZ:300653).
6, 5G construction.
Shennan Electric Road (SZ:002916), SangYi Technology (SH:600183), Hudian shares (SZ:002463), Wave Information (SZ:000977), China Science and Technology Shuguang (SH:603019), halo new network (SZ:300383).